ARA-290 16 MG

Dragon Pharma ARA-290 16 mg – Synthetic EPO-Derived Peptide for Innate Repair Research

Dragon Pharma ARA-290 16 mg is a synthetic 11-amino-acid peptide, also known as cibinetide, derived from erythropoietin (EPO). This engineered peptide has been specifically designed to activate the body's innate repair receptor (IRR), a mechanism that reduces inflammation and neuropathic pain without stimulating red blood cell production, making it a valuable tool for investigating tissue repair and inflammatory pathways.

Each vial contains 16 mg of lyophilized ARA-290 in a 2 mL format, requiring reconstitution with bacteriostatic water before use. The unique design of ARA-290 separates its tissue-protective effects from the erythropoietic activity of full-length EPO, providing researchers with a targeted tool for studying innate repair mechanisms. For related research compounds, explore our peptides category and specifically SS-31 50 mg for complementary mitochondrial and tissue protection research.

What Makes ARA-290 Valuable in Research?

ARA-290 represents a significant advancement in the study of tissue repair and inflammation. By specifically targeting the innate repair receptor, this peptide activates cytoprotective signaling pathways without the erythropoietic side effects associated with full-length EPO. Its 11-amino-acid structure has been optimized to retain the tissue-protective properties of EPO while eliminating its hematopoietic activity.

Researchers value ARA-290 for its specificity and targeted mechanism of action. Its ability to reduce inflammation, promote tissue repair, and modulate neuropathic pain pathways makes it relevant to research areas including neurology, immunology, and regenerative medicine. For investigators exploring other aspects of neuroprotection, Semax offers complementary research avenues in neurological function and repair.

Current scientific literature on ARA-290 can be accessed through the PubMed database, where researchers can review peer-reviewed studies on its biological activity and experimental applications.

Key Research Applications for Dragon Pharma ARA-290

• ✔ Investigation of innate repair receptor signaling pathways
• ✔ Evaluation of anti-inflammatory mechanisms and cytokine modulation
• ✔ Research on neuropathic pain and neuroprotection
• ✔ Studies of tissue repair and regeneration
• ✔ Preclinical models of inflammatory and neurodegenerative conditions

Product Details

Dosage & Usage Guidelines

Reconstitution Protocol

• ✔ Use sterile bacteriostatic water for injection
• ✔ Add appropriate volume to achieve desired concentration
• ✔ Swirl gently to dissolve – do not shake vigorously
• ✔ Store reconstituted solution at 2–8°C

Reconstitute the lyophilized powder using bacteriostatic water to a concentration suitable for your research protocol. The 16 mg format allows for flexible dosing across a range of experimental models. Always use aseptic technique during preparation to maintain peptide integrity.

Typical Research Parameters

In research settings, ARA-290 is typically administered via subcutaneous or intravenous injection. Dosing schedules and concentrations vary widely depending on the experimental design, animal model, and specific research objectives.

• ✔ Commonly used in inflammation and neuropathic pain studies
• ✔ Often combined with histological and molecular analysis
• ✔ Used to investigate innate repair receptor signaling pathways
• ✔ Research models include inflammatory and neurodegenerative paradigms

Factors to Consider in Research Protocols

• Targeted peptide with specific innate repair receptor activation
• Reconstitution stability is limited; prepare fresh solutions for each use
• Individual variation in response may be observed across subjects
• Storage conditions significantly impact peptide stability

Lab Testing & Batch Transparency

Lab status

COA pending release

Third-party analytical testing (COA) for Dragon Pharma ARA-290 16 mg is currently not yet available. Batch-specific assay data, purity analysis, and verification documentation will be published once released.

Testing Status

Pending

COA Availability

Not yet published

Batch Verification

In progress

Update

Coming soon

Transparency note: Dragon Pharma publishes batch-specific lab reports once analytical testing is completed and verified.

Awaiting COA

Shipping & Product Authenticity

What to Expect

• ✔ Orders are processed after payment confirmation
• ✔ USA Domestic shipping is typically faster when local stock is selected
• ✔ International orders include tracking, though update frequency may vary by destination
• ✔ Multiple warehouses may result in separate shipments when applicable

For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.

Storage

Store the lyophilized powder at controlled room temperature (15–25°C) in a dry, dark place, away from direct light and moisture. The unopened vial should be kept in its original packaging to maintain stability.

After reconstitution, store the solution at 2–8°C and use within 14 days. Do not freeze. Discard any unused portion after the recommended storage period. Before use, inspect the solution and avoid use if it appears cloudy, discolored, or contains particulate matter, or if the vial or seal is compromised.

Keep out of reach of children. Follow proper handling and sterile injection practices during research use.

Proper storage conditions help maintain product stability and consistent performance across the product's shelf life.

Frequently Asked Questions